Conference Reports for NATAP

Back

Digestive Disease Week (DDW) May 18-21, 2013 Orlando, FL     Simeprevir with Peginterferon/ribavirin for Treatment of Chronic HCV Genotype 1 Infection in Patients Who Relapsed After Previous Interferon-based Therapy: Results from PROMISE, a Phase III Trial - (05/22/13)   Response to 3 DAAs + RBV by Patient Characteristics: INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333, AND RIBAVIRIN ACHIEVE HIGH SUSTAINED VIROLOGIC RESPONSE 12 WEEKS POST-TREATMENT (SVR12) RATES IN PATIENTS WITH CHRONIC HCV GENOTYPE 1 REGARDLESS OF RACE, ETHNICITY, OR OTHER BASELINE CHARACTERISTICS - (05/21/13)   Key Drivers and Barriers to Treatment Initiation and Adherence in Individuals with Hepatitis C - (05/21/13)   Prevalence, Treatment, and Comorbidities of Hepatitis C Infection (HCV) Among Patients With Commercial and Medicaid Insurance - (05/21/13)   Final Results PROVIDE Study: Boceprevir in null-responders   - (05/21/13)   An Analysis of Response Rates by Fibrosis Stage in Patients Treated With Faldaprevir, BI 207127, and Ribavirin in the SOUND-C2 Study - (05/20/13)